Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

NCT03225989 | Completed Phase 1 Results FDA Drug

• 1 other identifier: LOKON002
• Study Type: interventional
• Target: 47
• Locations: 1 country
• Sites: 2

Brief Summary

This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning. LOAd703 is administered by intratumoral image-guided injections. Maximum 50 patients can be enrolled. LOAd703 is an immunostimulatory gene therapy using an selection replication competent adenovirus as a gene vehicle. The virus is derived from serotype 5 adenovirus with the fiber from serotype 35. It expresses the transgenes trimerized membrane-bound isoleucine zipper (TMZ) TMZ-CD40L and 41BBL under control of a cytomegalovirus (CMV) promoter.

Conditions

Pancreatic Adenocarcinoma; Ovarian Cancer; Biliary Carcinoma; Colorectal Cancer

Outcome Measures

Primary Outcomes (2)

• Safety: Toxicity Symptoms Graded According to CTCAE v4.03.

  The toxicity symptoms were graded according to CTCAE v4.03.

  Up to 50 weeks

• Immune Reactions to LOAd703 Virus as Assessed by Anti-adenovirus Ig ELISA

  Fold change between baseline and evaluation visit for anti-adenovirus antibodies (LOAd703). The baseline is the last available measurement taken before the first LOAd703 treatment. Evaluation is a measurement taken from subjects receiving at least 3 LOAd703 treatments.

  Up to 50 weeks

Secondary Outcomes (7)

• Response on Tumor Size by Dose and Cancer Diagnosis

  Up to 50 weeks

• Overall Survival

  From registration date to date of death, assessed up to 40 months

• Time to Progression

  From registration date to date of progression, assessed up to 40 months

• Progression Free Survival

  From registration date to date of progression, or date of death, which ever came first, assessed up to 40 months

• Systemic Immune Activation

  Up to 50 weeks

Study Arms (1)

LOAd703

EXPERIMENTAL

LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)

Drug: LOAd703

Interventions

LOAd703 DRUG

Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL

LOAd703

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have histologic or cytologic evidence of colorectal carcinoma (CRC), pancreatic carcinoma (PC), biliary cancer, or epithelial ovarian carcinoma (EOC which may encompass epithelial ovarian, fallopian tube or primary peritoneal carcinoma).
• Have advanced disease, defined as cancer that is either metastatic or locally advanced, unresectable, and for which radiotherapy or other locoregional therapies are not considered treatment of choice but systemic chemotherapy or no therapy is planned.
• Have one of the following treatment situations apply:
• Colorectal carcinoma (CRC) I. A patient with refractory or recurrent metastatic CRC who has either received all conventional therapy; or is entering a "resting" phase between reasonable conventional treatments. II. A patient who is amenable to treatment with LOAd703 plus gemcitabine as a single agent conditioning regimen.
• Pancreatic cancer I. A patient with either locally advanced, unresectable or metastatic disease who is eligible to receive any line of conventional treatment consisting of gemcitabine and/or nab-paclitaxel. II. A patient who is amenable to treatment with LOAd703 as an "add-on" to standard-of-care gemcitabine-based or nab-paclitaxel- based regimens or gemcitabine or nab-paclitaxel as single agents. c. Biliary cancer I. A patient with either locally advanced unresectable or metastatic biliary cancer who is either treatment-naïve or has received any number of lines of treatment. II. Patient who is amenable to treatment with LOAd703 as an "add-on" to standard-of-care treatment consisting of gemcitabine combined with other agents (e.g. gemcitabine/low-dose cisplatin, gemcitabine/oxaliplatin, etc) in the first line setting or gemcitabine in a combination regimen or as a single agent in latter lines of treatment. d. Ovarian Cancer I. A patient with either epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
• II. The patient has either:
• i) Residual disease following first-line standard-of-care combination chemotherapy. ii) Platinum-sensitive disease (platinum free interval ≥ 6 months) in early relapse following first-line standard-of care combination chemotherapy. iii) Platinum-resistant disease and received at least 3 lines of standard treatment. These treatments should have included bevacizumab and/or PARP inhibitors if they are reasonable candidates for such. III. Amenable to treatment with LOAd703 as an "add-on" to standard-of-care paclitaxel-based regimens (excluding bevacizumab), paclitaxel as a single agent, or gemcitabine as a single agent.
• Have a disease burden that is considered low (i.e. low tumor burden), which is defined on a patient-by-patient basis as per principal investigator's discretion. A rough guideline for defining low tumor burden is that the sum of the product of the bidimensional measurements for all lesions is \< 70 cm2.
• Have a measurable disease by standard imaging techniques per RECIST criteria. Measurable lesions must be outside of any prior radiation field(s), unless disease progression has been documented at that disease site subsequent to radiation.
• At least one non-irradiated (or irradiated but disease progression documented at the site subsequent to radiation) lesion must be suitable for image-guided intratumoral injection and needle biopsy.
• Be medically suited to sedation if required during intratumoral injections.
• Be at least 18 years-old.
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
• Have no remaining acute toxic effects from previous anticancer therapy \> grade 1 except for any grade of alopecia.
• Have adequate baseline organ/hematological function, as demonstrated by the following:

You may not qualify if:

• Any concurrent treatment that would compromise the study including but not limited to continuous high dose corticosteroids (\>0.5mg/kg), lymphodepleting antibodies or cytotoxic agents.
• Treatment with high dose immune inhibitors including lymphotoxic monoclonal antibodies such as alemtuzumab (CampathR), or sirolimus (RapamuneR) and its analogs, biological therapy, cytotoxic agents or any investigational agents within 21 days of registration.
• Ovarian carcinoma patients should not be eligible to PARP inhibitor treatment.
• Patients on warfarin (or other anti-coagulants) are not eligible.
• Women who are pregnant, lactating, or planning to become pregnant during the study period, or women of childbearing potential who are not using acceptable contraceptive methods. A woman is considered of childbearing potential if she is not surgically sterile or is less than 1 year since last menstrual period. Acceptable contraceptive methods are: combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion and vasectomized partner.
• Men who do not consent to the use of condom during intercourse during study participation.
• Known active hepatitis B or C infection, or HIV infection.
• Patients with active, severe, autoimmune disease.
• Uncontrolled intercurrent illness including but not limited to psychiatric illness/social situations that in the opinion of the Investigator would compromise compliance of study requirements or put the patient at unacceptable risk.
• Other malignancies within the past 2 years (not including basal and squamous cell carcinoma of the skin, localized prostate cancer or in situ cervix carcinoma).
• Patients must agree to not to vaccinate with living vaccines during participation in the trial.

Sponsors & Collaborators

• Lokon Pharma AB: lead
• Uppsala University: collaborator

Study Sites (2)

Karolinska University Hospital, Huddinge

Stockholm, 141 86, Sweden

Location

Uppsala University Hospital

Uppsala, 75185, Sweden

Location

MeSH Terms

Conditions

Ovarian Neoplasms; Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Results Point of Contact

• Title: Angelica Loskog CEO
• Organization: Lokon Pharma

angelica.loskog@lokonpharma.com

+46 18-50 74 44

Study Officials

• Angelica Loskog, PhD

  Lokon Pharma AB

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants treated with LOAd703 at three dose levels (5x10e10 VP, 1x10e11 VP, 5x10e11 VP) and SOC tailored to the indication

Study Record Dates

• First Submitted: July 4, 2017
• First Posted: July 21, 2017
• Study Start: March 1, 2018
• Primary Completion: August 22, 2023
• Study Completion: August 22, 2023
• Last Updated: November 19, 2024
• Results First Posted: November 19, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

SE (2)